Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer

Brachytherapy

Volumn 14, Issue 5, 2015, Pages 587-599

  Schwarz, Julie K ^a   Beriwal, Sushil ^b   Esthappan, Jacqueline ^a   Erickson, Beth ^c   Feltmate, Colleen ^d   Fyles, Anthony ^e   Gaffney, David ^f   Jones, Ellen ^g   Klopp, Ann ^h   Small, William ⁱ   Thomadsen, Bruce ^j   Yashar, Catheryn ^k   Viswanathan, Akila ^d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ LOYOLA UNIVERSITY CHICAGO   (United States)

^j UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^k UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

more..

Author keywords

Brachytherapy; Endometrial carcinoma; Magnetic resonance imaging

Indexed keywords

ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; DOSIMETRY; ENDOMETRIUM CANCER; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; INOPERABLE CANCER; MYOMETRIUM; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY CONTROL; THREE DIMENSIONAL IMAGING; TREATMENT PLANNING; TUMOR VOLUME; ADVERSE EFFECTS; CARCINOMA; ENDOMETRIAL NEOPLASMS; ORGANS AT RISK; PATHOLOGY; PRACTICE GUIDELINE; PROCEDURES; RADIOGRAPHY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING SYSTEM;

BRACHYTHERAPY; CARCINOMA; CONSENSUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; ORGANS AT RISK; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 84940028442     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2015.06.002     Document Type: Article

References (49)

1. Fader A.N., Arriba L.N., Frasure H.E., von Gruenigen V.E. Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 2009, 114:121-127.
2. Available at: Accessed January 15, 2015. http://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine-cancer-key-statistics.
3. ACR-ASTRO practice parameter for the performance of low-dose-rate brachytherapy Available at:, Accessed May 11, 2015. http://www.acr.org/~/media/47FA0E05C5484F9FBB9F0E5116169742.pdf.
4. ACR-ASTRO parameter for the performance of high-dose-rate brachytherapy American College of Radiology, Available at:, Accessed May 11, 2015. http://www.acr.org/~/media/B563249005D447DA9C3CEF1ABCACBED2.pdf.
5. Baker J., Obermair A., Gebski V., Janda M. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: A meta-analysis and systematic review of the literature. Gynecol Oncol 2012, 125:263-270.
6. Cade T.J., Quinn M.A., Rome R.M., Neesham D. Progestogen treatment options for early endometrial cancer. BJOG 2010, 117:879-884.
7. Randall T.C., Kurman R.J. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997, 90:434-440.
8. Wang C.B., Wang C.J., Huang H.J., et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer 2002, 94:2192-2198.
9. Ushijima K., Yahata H., Yoshikawa H., et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007, 25:2798-2803.
10. Orbo A., Vereide A., Arnes M. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: A national multicentre randomised trial. BJOG 2014, 121:477-486.
11. Gallos I.D., Shehmar M., Thangaratinam S., et al. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: A systematic review and metaanalysis. Am J Obstet Gynecol 2010, 203:547.e1-547.e10.
12. Nilsson C.G., Haukkamaa M., Vierola H., et al. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) 1982, 17:529-536.
13. Gunderson C.C., Fader A.N., Carson K.A., et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: A systematic review. Gynecol Oncol 2012, 125:477-482.
14. Montz F.J., Bristow R.E., Bovicelli A., et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002, 186:651-657.
15. Ma B.B., Oza A., Eisenhauer E., et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers-A study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 2004, 14:650-658.
16. Mikuta J.J. International Federation of Gynecology and Obstetrics staging of endometrial cancer 1988. Cancer 1993, 71:1460-1463.
17. Beddy P., O'Neill A.C., Yamamoto A.K., et al. FIGO staging system for endometrial cancer: Added benefits of MR imaging. Radiographics 2012, 32:241-254.
18. Wu L.M., Xu J.R., Gu H.Y., et al. Predictive value of T2-weighted imaging and contrast-enhanced MR imaging in assessing myometrial invasion in endometrial cancer: A pooled analysis of prospective studies. Eur Radiol 2013, 23:435-449.
19. Crivellaro C., Signorelli M., Guerra L., et al. Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: The role of 18F-FDG PET/CT. Gynecol Oncol 2013, 130:306-311.
20. Antonsen S.L., Jensen L.N., Loft A., et al. MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer-A multicenter prospective comparative study. Gynecol Oncol 2013, 128:300-308.
21. Selman T.J., Mann C.H., Zamora J., et al. A systematic review of tests for lymph node status in primary endometrial cancer. BMC Womens Health 2008, 8:8.
22. Chang M.C., Chen J.H., Liang J.A., et al. 18F-FDG PET or PET/CT for detection of metastatic lymph nodes in patients with endometrial cancer: A systematic review and meta-analysis. Eur J Radiol 2012, 81:3511-3517.
23. Lee J.H., Dubinsky T., Andreotti R.F., et al. ACR appropriateness criteria(R) pretreatment evaluation and follow-up of endometrial cancer of the uterus. Ultrasound Q 2011, 27:139-145.
24. Creasman W.T., Morrow C.P., Bundy B.N., et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987, 60:2035-2041.
25. Kang S., Kang W.D., Chung H.H., et al. Preoperative identification of a low-risk group for lymph node metastasis in endometrial cancer: A Korean gynecologic oncology group study. J Clin Oncol 2012, 30:1329-1334.
26. Beriwal S., Kim H., Heron D.E., et al. Comparison of 2D vs. 3D dosimetry for Rotte 'Y' applicator high dose rate brachytherapy for medically inoperable endometrial cancer. Technol Cancer Res Treat 2006, 5:521-527.
27. Mock M., Knocke T., Fellner C., et al. Analysis of different application systems and CT-controlled planning variants in treatment of primary endometrial carcinomas. Is brachytherapy treatment of the entire uterus technically possible?. Strahlenther Onkol 1998, 174:320-328.
28. Johnson S.B., Zhou J., Jolly S., et al. The dosimetric impact of single, dual, and triple tandem applicators in the treatment of intact uterine cancer. Brachytherapy 2013, 13:268-274.
29. Nag S., Erickson B., Parikh S., et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 2000, 48:779-790.
30. Nguyen T.V., Petereit D.G. High-dose-rate brachytherapy for medically inoperable stage I endometrial cancer. Gynecol Oncol 1998, 71:196-203.
31. Weitmann H.D., Potter R., Waldhausl C., et al. Pilot study in the treatment of endometrial carcinoma with 3D image-based high-dose-rate brachytherapy using modified Heyman packing: clinical experience and dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2005, 62:468-478.
32. Gill B.S., Kim H., Houser C., et al. Image-based three-dimensional conformal brachytherapy for medically inoperable endometrial carcinoma. Brachytherapy 2014, 13:542-547.
33. Georg P., Lang S., Dimopoulos J.C., et al. Dose-volume histogram parameters and late side effects in magnetic resonance image-guided adaptive cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys 2011, 79:356-362.
34. Bastin K., Buchler D., Thomadsen B., et al. Heyman's-based model for high dose rate multitandem intracavitary brachytherapy. Endocurie/Hyperthermia Oncol 1993, 9:9-13.
35. Heyman J., Reuterwall O., Benner S. The Radiumhemmet experience with radiotherapy in cancer of the corpus of the uterus. Acta Radiol 1941, 22:11-94.
36. Nag S., Orton C., Young D., et al. The American brachytherapy society survey of brachytherapy practice for carcinoma of the cervix in the United States. Gynecol Oncol 1999, 73:111-118.
37. Colombo N., Preti E., Landoni F., et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(Suppl. 6):vi35-vi39.
38. Emons G., Kimmig R. Interdisciplinary S2k guidelines on the diagnosis and treatment of endometrial carcinoma. J Cancer Res Clin Oncol 2009, 135:1387-1391.
39. Fung-Kee-Fung M., Dodge J., Elit L., et al. Follow-up after primary therapy for endometrial cancer: A systematic review. Gynecol Oncol 2006, 101:520-529.
40. Sartori E., Pasinetti B., Chiudinelli F., et al. Surveillance procedures for patients treated for endometrial cancer: A review of the literature. Int J Gynecol Cancer 2010, 20:985-992.
41. Chao C.K., Grigsby P.W., Perez C.A., et al. Brachytherapy-related complications for medically inoperable stage I endometrial carcinoma. Int J Radiat Oncol Biol Phys 1995, 31:37-42.
42. Barnes E.A., Thomas G., Ackerman I., et al. Prospective comparison of clinical and computed tomography assessment in detecting uterine perforation with intracavitary brachytherapy for carcinoma of the cervix. Int J Gynecol Cancer 2007, 17:821-826.
43. Segedin B., Gugic J., Petric P. Uterine perforation-5-year experience in 3-D image guided gynaecological brachytherapy at Institute of Oncology Ljubljana. Radiol Oncol 2013, 47:154-160.
44. Schaner P., Caudell J., De Los Santos J., et al. Intraoperative ultrasound guidance during intracavitary brachytherapy applicator placement in cervical Cancer. Int J Gynecol Cancer 2013, 23:559-566.
45. Aydeniz B., Gruber I.V., Schauf B., et al. A multicenter survey of complications associated with 21,676 operative hysteroscopies. Eur J Obstet Gynecol Reprod Biol 2002, 104:160-164.
46. Ben-Baruch G., Menczer J., Shalev J., et al. Uterine perforation during curettage: Perforation rates and postperforation management. Isr J Med Sci 1980, 16:821-824.
47. Available at: Accessed January 20, 2015. http://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.
48. Townamchai K., Poorvu P.D., Damato A.L., et al. Radiation dose escalation using intensity modulated radiation therapy for gross unresected node-positive endometrial cancer. Pract Radiat Oncol 2014, 4:90-98.
49. Poorvu P.D., Sadow C.A., Townamchai K., et al. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes. Int J Radiat Oncol Biol Phys 2013, 85:1262-1268.